Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theodoros Foukakis

Showing results (121-130 of 128) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 128 results.
British Journal of Cancer|January 18, 2020
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.
British Journal of Cancer|April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.
BMJ Open|August 27, 2025
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNEAlexios Matikas, Bjørn Naume, Hans Wildiers, et al.
The Journal of Clinical Investigation|November 15, 2023
FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persistersMengjiao Li, Tatsunori Nishimura, Yasuto Takeuchi, et al.
Nature Communications|June 24, 2026
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world studyDavide Massa, Theodoros Foukakis, Sylvie Giacchetti, et al.
Breast Cancer Research and Treatment|February 18, 2026
Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancerEileen Shinn, David Zahrieh, Angela DeMichele, et al.
Breast Cancer Research and Treatment|March 27, 2025
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancerEileen Shinn, David Zahrieh, Angela DeMichele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2023
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS TrialGeorg Pfeiler, Dominik Hlauschek, Erica L Mayer, et al.
Pageof 13

Showing results (121-130 of 128) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 128 results.
British Journal of Cancer|January 18, 2020
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.
British Journal of Cancer|April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.
BMJ Open|August 27, 2025
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNEAlexios Matikas, Bjørn Naume, Hans Wildiers, et al.
The Journal of Clinical Investigation|November 15, 2023
FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persistersMengjiao Li, Tatsunori Nishimura, Yasuto Takeuchi, et al.
Nature Communications|June 24, 2026
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world studyDavide Massa, Theodoros Foukakis, Sylvie Giacchetti, et al.
Breast Cancer Research and Treatment|February 18, 2026
Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancerEileen Shinn, David Zahrieh, Angela DeMichele, et al.
Breast Cancer Research and Treatment|March 27, 2025
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancerEileen Shinn, David Zahrieh, Angela DeMichele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2023
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS TrialGeorg Pfeiler, Dominik Hlauschek, Erica L Mayer, et al.
Pageof 13